Last updated date
ABOUT THIS STUDY
The purpose of this trial is to determine the equivalence of 3 new formulations of a Premarin®/medroxyprogesterone acetate (MPA) combination tablet to the currently marketed dosage form (Prempro® [TM]). This study will be performed in healthy postmenopausal women. Each subject will participate in the study for approximately 14 weeks, including a screening evaluation within 3 weeks before the study, and four, 6-day, 5-night inpatient periods with at least a 21-day washout interval between each dose administration.
TRY A NEW SEARCH
Search for Clinical Trials by condition, keyword or trial number. Share your location or enter your city or zip code to find studies near you.
Based on your search, you may also be interested in
MenopauseStudy Evaluating DVS-233 SR for Treatment of Vasomotor Symptoms Associated With Menopause
- Del. Cuauhtemoc,
- Lomas Virrteyes,
- Den Bosch,
MenopauseStudy Comparing 3 New Formulations of Premarin® 0.625 mg/MPA 2.5 mg With a Reference Formulation
MenopauseBioequivalence Study Of Bazedoxifene/Conjugated Estrogen Tablets In Postmenopausal Women
MenopauseStudy Evaluating Bazedoxifene/Conjugated Estrogens Combinations In Healthy Postmenopausal Women